In this setting, by controlling the NRF2/HO-1 pathway, which contributes to raising GSH levels, SIRT5 confers resistance to genotoxic chemotherapeutics such as cisplatin, thereby supporting tumor growth [126]. This evidence concerns the gene SIRT5 and neoplasm.